News | January 26, 2012

Heart Hospital of Austin Among First Approved for TAVR Since FDA Clearance

January 26, 2012 — Heart Hospital of Austin opened a heart valve clinic, the first of its kind in the region. The clinic gives new hope to patients with severe aortic stenosis who were previously considered inoperable, offering a multidisciplinary approach to evaluating such cases. Interventional cardiologists and cardiac surgeons at the clinic will collaboratively identify patients who may be eligible for a new, catheter-based valve replacement procedure -- transcatheter aortic valve replacement (TAVR) -- instead of traditional, open-chest procedures. Heart Hospital of Austin is among the first sites in the nation to receive this TAVR technology since the U.S. Food and Drug Administration (FDA) approved it in November 2011.

"This is truly a collaborative approach to valve replacement that will provide another option for patients who are not candidates for open-chest surgery due to advanced age, or because they are too ill or suffering from additional medical conditions," Faraz Kerendi, M.D., a cardiothoracic surgeon at Cardiothoracic and Vascular Surgeons, which practices at Heart Hospital of Austin, said. "Prior to this procedure … [patients] were often given only months to live."

Severe aortic stenosis is a condition in which the opening of the aortic valve becomes narrow, restricting blood flow from the heart.

"Over time, the valve can become calcified, preventing it from opening and releasing the blood properly," Juhana Karha, M.D., an interventional cardiologist at Heart Hospital of Austin and with Austin Heart, said. "Open-chest surgery is the traditional treatment method for this condition, but catheter-based valve replacement gives hope to patients who cannot undergo surgery for a variety of reasons."

Symptoms of severe aortic stenosis include chest pain and chest pressure. It can also cause blood to back up into the lungs, resulting in shortness of breath and other breathing problems. Left untreated, this condition is often fatal.

Transcatheter aortic valve replacement consists of inserting a valve — which has been developed to shrink down to the size of a pencil —  through the groin via catheter, up to the aorta. After the catheter is advanced through the aorta and aortic valve, it is positioned and then opened with a balloon.

Transcatheter aortic valve replacement results in a shorter recovery time — one to two weeks, versus six to eight weeks for traditional surgery — and a much smaller incision. More importantly, it prevents the need for physicians to utilize a heart bypass machine. This new technology allows the patient's heart to beat on its own throughout the entire procedure.

The first transcatheter aortic valve replacement procedure is expected to take place in February.

For more information: www.hearthospitalofaustin.com, www.austinheart.com

Related Content

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
News | Heart Valve Technology | January 15, 2019
Boston Scientific Corp. and Edwards Lifesciences Corp. announced that the companies have reached an agreement to settle...
The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as a arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital. Dr. Dominick Wiktor. The TEE is from a Philips Epiq system.

The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as an arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital.

Feature | Heart Valve Technology | January 14, 2019 | Allen Atchley, M.D., FACC, The Chattanooga Heart Institute
Mitral regurgitation (MR) is one of the most common types of heart valve diseases in the United States, affecting app
JC Medical Announces First U.S. Treatment With J-Valve TAVR Device
News | Heart Valve Technology | January 07, 2019
January 7, 2019 — JC Medical announced the successful treatment of the first U.S.
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug Administration (FDA...
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
Overlay Init